Given that MYC, SLC1A5, and mTORC1 levels are higher in glutamine-addicted cancer cells, along with glutaminase levels, all of these can be exploited in future clinical studies as biomarkers to identify patients when assessing the potential effectiveness of glutaminolysis inhibitors. This evidence concerns the gene MYC and cancer.